Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130806
Status:
TERMINATED
Last Update Posted:
2016-09-07
First Post:
2005-08-12
Brief Title:
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes 0478-065
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Study to Assess the Efficacy and Tolerability of MK0478 Muraglitazar Also BMS 298585 Coadministered With Insulin in Patients With Type 2 Diabetes
Status:
TERMINATED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes a specific type of diabetes who are not currently treated with insulin
Detailed Description:
The duration of treatment is 30 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_020 | None | None | None |